Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

Next Previous
Trial Profile

A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixavir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors TaiGen Biotechnology

Most Recent Events

  • 16 Dec 2020 Status changed from recruiting to completed, according to a Taigen biotech media release.
  • 31 Aug 2020 According to a TaiGen Biotechnology media release, based on the test results of the four dose groups, the dose for the phase 2 clinical trial will be determined.
  • 31 Aug 2020 According to a TaiGen Biotechnology media release, the fifth and sixth dose groups and food cross-effect of this study will be carried out successively.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top